92501-98-9

Upstream product

• 100-43-6 4-vinylpyridine 
• 105-53-3 diethyl malonate 

Downstream Products

• 1026564-84-0 4-[3-({[(S)-2-Benzyloxycarbonyl-1-((S)-1-benzyloxycarbonyl-2-cyclohexyl-ethylcarbamoyl)-ethylcarbamoyl]-methyl}-ethyl-carbamoyl)-propyl]-piperidine-1-carboxylic acid tert-butyl ester 
• 1026853-21-3 4-[3-({[(S)-2-Benzyloxycarbonyl-1-((R)-1-benzyloxycarbonyl-2-cyclohexyl-ethylcarbamoyl)-ethylcarbamoyl]-methyl}-ethyl-carbamoyl)-propyl]-piperidine-1-carboxylic acid tert-butyl ester 
• 194933-88-5 4-[3-({[(S)-2-Benzyloxycarbonyl-1-((S)-1-benzyloxycarbonyl-2-methyl-propylcarbamoyl)-ethylcarbamoyl]-methyl}-ethyl-carbamoyl)-propyl]-piperidine-1-carboxylic acid tert-butyl ester 
• 169512-83-8 N-[N-[N-(4-(N-BOC-piperidin-4-yl)butanoyl)-N-ethylglycyl]aspartyl]-β-cyclohexylalanine 
• 1025970-90-4 4-[3-({[(S)-2-Benzyloxycarbonyl-1-((S)-1-benzyloxycarbonyl-2-cyclooctyl-ethylcarbamoyl)-ethylcarbamoyl]-methyl}-ethyl-carbamoyl)-propyl]-piperidine-1-carboxylic acid tert-butyl ester 

Relevant academic research and scientific papers

Novel 1,8-naphthyridin-2(1h)-one derivatives

The purpose is to provide selective PDE IV inhibitors which have a potent anti-asthmatic profile with excellent safety. A compound of the formula (1): wherein: A is an unsubstituted or optionally substituted 5 or 6 membered heteroaryl group or a fused benzene ring in which any of the above-defined heteroaryl groups is fused to a benzene ring, B is carbon or nitrogen, R1 is hydrogen, lower alkyl, trifluoromethyl, hydroxyl, lower alkoxy, a residue derived from a carboxylic acid or a derivative thereof, amino, or an amino nitrogen-containing group, R2 is hydrogen, halogen, cyano, nitro, lower alkylthio, lower alkylsulfinyl, lower alkylsulfonyl, trifluoromethyl, hydroxyl, lower alkoxy, a residue derived from a carboxylic acid or a derivative thereof, amino, or an amino nitrogen-containing group, and m is an integer of from 1 to 8, both inclusive; or a pharmaceutically acceptable salt thereof possesses selective PDE IV inhibition and is useful as a pharmaceutical drug, preferably an anti-asthmatic, etc.

Design of a new class of orally active fibrinogen receptor antagonists

The integrin receptor recognition sequence Arg-Gly-Asp was successfully used as a template from which to develop a series of potent, selective, orally active, peptide-based fibrinogen receptor antagonists with a long duration of action. Simple modifications centered on the Arg and Gly residues quickly led to a modified peptide (1) with significantly enhanced ability to inhibit in vitro platelet aggregation. Substitution of the guanidino group in 1 by piperidine provided 3, which showed not only a further increase in potency but also a modest degree of oral efficacy. Finally, exploration of the nature of the C-terminal amino acid, with respect to its side-chain functionality and the carboxy terminus, yielded a group of molecules that showed excellent in vitro potency for inhibiting platelet aggregation, excellent integrin selectivity, a high level of oral efficacy, and an extended duration of action.

Tartronic acids, their acetalic ethers and O-esters

Tartronic acid acetalic ethers and esters of the general formula: STR1 are provided and are useful in treatment of bone dysmetabolism. As examples, Ra and Rb may be hydrogen, B is a C2 -C12 acyl group, R is phenyl and n is 0-12.